SV Life Sciences said Tuesday that it has hired Michael Balmuth as a partner. Previously, Balmuth worked at Edison Ventures where he was a general partner.
BOSTON, MA; SAN FRANCISCO CA; LONDON, UK (July 8, 2014): SV Life Sciences (“SVLS”), a leading, international life sciences venture capital firm, today announced the appointment of Michael Balmuth as Partner.
Mr. Balmuth joins SVLS’ Healthcare Services team, a highly experienced group that looks to partner with accomplished management teams with innovative business plans and scalable platforms. He will play a leading role in directing the firm’s activities within the healthcare information technology (“HCIT”) sector while building on SVLS’ past successes including investments in Homecare Homebase and Phase Forward.
For over 25 years, Mr. Balmuth has worked in the technology industry as a venture capital investor, investment banker and technology executive. Before joining SVLS, Mr. Balmuth was a General Partner at Edison Ventures where he was head of the firm’s HCIT practice. Prior to Edison, Mr. Balmuth was a General Partner at Summit Partners. While at Summit, he led the East Coast office for the Summit Accelerator Fund from its inception. As an investment banker with Broadview International, Mr. Balmuth advised on M&A transactions and equity investments totaling over $1 billion. Mr. Balmuth began his career at IBM in various roles including sales, marketing, corporate development and systems engineering. Mr. Balmuth received a B.A. in Engineering Sciences from Dartmouth College and an M.B.A. from Harvard Business School.
“We enthusiastically welcome Mike to SVLS,” commented Gene Hill, Chairman of SVLS. “The vast knowledge he gained from investing in and developing software and information technologies across the healthcare industry will significantly strengthen SVLS’ diverse set of skills and competencies.”
“Mike is a talented and experienced executive who is a valuable addition to our team,” said Tom Flynn, Managing Partner in SVLS’ Healthcare Services practice. “Mike’s arrival reinforces SVLS’ deep domain expertise and continued focus on healthcare services and HCIT investments in late stage growth equity deals.”
Mr. Balmuth stated, “Joining SVLS is a great opportunity to work with one of the industry’s leading firms dedicated to life sciences investing. I look forward to applying my healthcare IT experience to build value in the Firm’s existing and future investments in innovative solutions for providers, payers, patients, employers and life sciences companies.”
About SV Life Sciences
SV Life Sciences is a leading, international life sciences venture capital firm. SVLS affiliated funds have been investing in life sciences companies since the early 1980s and the Firm closed its first dedicated life sciences fund in 1994. SVLS’ team of 32 professionals is organized according to experience and specialization into three practice areas:
Biotechnology/Biopharmaceuticals, Medical Devices/Instrumentation, and Healthcare Services/Healthcare IT. These individuals’ diverse and complementary skill sets and experiences enable SVLS to tailor an investment team for almost any life science business. Typically, SVLS recruits operating executives, called Venture Partners, who have distinguished careers in the life sciences fields and can bring extensive operating expertise to the SVLS portfolio of investments. They assist in sourcing, building and exiting investments successfully. In some cases, these individuals are promoted to serve as Partners and/or Managing Partners within the Firm. SVLS employs a close symbiosis between operating and financial professionals which has led to significant success over five investment funds. SVLS has offices in Boston, London and San Francisco. For more information, please visit the company’s website at http://www.svlsa.com.
Take your pick!
- Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
- VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now.